Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 25%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics Inc. exhibits a positive financial outlook driven by a meaningful increase in Chromium reaction volumes, indicating a robust market for its integrated solutions in analyzing biological systems. Despite ongoing pricing pressure, the company has seen consumable sales growth outpacing instrument revenue, with projections suggesting a potential increase of 5 to 19 times in consumables by platform by 2027. The firm's diverse product offerings and strong geographical revenue foundation, primarily from the United States, further reinforce its competitive position in the life science technology sector.

Bears say

10x Genomics is facing significant challenges, evidenced by a contraction in 2024 marked by double-digit pricing pressure and stagnant to declining volumes, with growth projections not anticipated to improve until 2027. The company's fourth-quarter earnings revealed a notable miss in expected EPS and a full-year revenue outlook that fell short of market expectations, indicating ongoing operational difficulties. As a result, despite recent market expansions, 10x Genomics has experienced a decline of over 90% in stock value since its peak in 2021, reflecting investor disappointment and lack of confidence in its recovery trajectory.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.